NEW YORK, July 24 – Applera said Tuesday that it would spend $75 million over the next year to establish a wide-ranging drug discovery program across its three businesses, Celera Genomics, Celera Diagnostics, and Applied Biosystems.

The initiative would seek to commercialize therapeutic and diagnostic products based on its genomic and SNP data. The three Applera companies would make equal funding contributions to the program.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.

Genetic genealogy has led to an arrest in another cold case, dating back to 1987.

Wired reports that 23andMe is trying to bolster its outside collaborations.

In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.